Oral Inhalation System Delivers Morphine Doses

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 2
Volume 9
Issue 2

VIENNA, Austria-A new oral inhalation system for morphine is almost as efficient as IV dosing, Aradigm Corp and SmithKline Beecham researchers reported at the 9th World Congress on Pain. B. A. Otulana, MD, said that the dose-corrected bioavailability of morphine with the new device was 75% of that with intravenous morphine, a major increase over the 5% bioavailability achieved with other nebulizers. This approach might provide a useful, noninvasive alternative to parenteral morphine administration.

VIENNA, Austria—A new oral inhalation system for morphine is almost as efficient as IV dosing, Aradigm Corp and SmithKline Beecham researchers reported at the 9th World Congress on Pain. B. A. Otulana, MD, said that the dose-corrected bioavailability of morphine with the new device was 75% of that with intravenous morphine, a major increase over the 5% bioavailability achieved with other nebulizers. This approach might provide a useful, noninvasive alternative to parenteral morphine administration.

The Aradigm device uses disposable liquid dosage forms and a hand-held nebulizer to produce fine aerosol particles that can penetrate deep into the lungs. It was tested in comparison to intravenous morphine in 10 healthy adult subjects in an open-label crossover trial.

On separate days, subjects took either 4 mg of morphine IV or four inhalations of aerosolized morphine (a total dose of 8.8 mg). Plasma morphine levels were measured at baseline and for 4 hours after dosing. Both inhaled and intravenous morphine reached peak plasma concentrations in less than 2 minutes after dosing. Dr. Otulana said that relative Cmax (ng/mL) bioavailability of the inhaled dose was 78%, while the area under the curve (AUC) ratio was 163.8% (Table).

This suggests that, at least in healthy volunteers, the morphine inhalation device provides efficient delivery of morphine and a pharmacokinetic profile similar to that of intravenous morphine, Dr. Otulana concluded.

Recent Videos
4 experts in this video
4 experts in this video
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
7 experts are featured in this series.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
Related Content